PureTech Health (PRTC)
PureTech Health Statistics
Share Statistics
PureTech Health has 24.02M shares outstanding. The number of shares has increased by 8.48% in one year.
| Shares Outstanding | 24.02M |
| Shares Change (YoY) | 8.48% |
| Shares Change (QoQ) | 0.32% |
| Owned by Institutions (%) | 0.14% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 8,712 |
| FTD / Avg. Volume | 179.19% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.19 and the forward PE ratio is -2.59. PureTech Health's PEG ratio is 0.
| PE Ratio | -1.19 |
| Forward PE | -2.59 |
| PS Ratio | 23.38 |
| Forward PS | 0.9 |
| PB Ratio | 0.17 |
| P/FCF Ratio | -0.73 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for PureTech Health.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.76, with a Debt / Equity ratio of 0.05.
| Current Ratio | 6.76 |
| Quick Ratio | 6.76 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -2.18 |
| Debt / FCF | -0.24 |
| Interest Coverage | -10.84 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37,000 |
| Profits Per Employee | $-729,966.67 |
| Employee Count | 90 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 30.52M |
| Effective Tax Rate | -84.55% |
Stock Price Statistics
The stock price has increased by -36.86% in the last 52 weeks. The beta is 1.25, so PureTech Health's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -36.86% |
| 50-Day Moving Average | 17.49 |
| 200-Day Moving Average | 19.86 |
| Relative Strength Index (RSI) | 53.78 |
| Average Volume (20 Days) | 4,862 |
Income Statement
In the last 12 months, PureTech Health had revenue of 3.33M and earned -65.7M in profits. Earnings per share was -23.8.
| Revenue | 3.33M |
| Gross Profit | -1.6M |
| Operating Income | -146.2M |
| Net Income | -65.7M |
| EBITDA | -11.63M |
| EBIT | -16.56M |
| Earnings Per Share (EPS) | -23.8 |
Balance Sheet
The company has 191.08M in cash and 25.34M in debt, giving a net cash position of 165.74M.
| Cash & Cash Equivalents | 191.08M |
| Total Debt | 25.34M |
| Net Cash | 165.74M |
| Retained Earnings | 83.82M |
| Total Assets | 579.95M |
| Working Capital | 370.5M |
Cash Flow
In the last 12 months, operating cash flow was -105.92M and capital expenditures -245K, giving a free cash flow of -106.16M.
| Operating Cash Flow | -105.92M |
| Capital Expenditures | -245K |
| Free Cash Flow | -106.16M |
| FCF Per Share | -3.84 |
Margins
Gross margin is -48.14%, with operating and profit margins of -4390.36% and -1972.88%.
| Gross Margin | -48.14% |
| Operating Margin | -4390.36% |
| Pretax Margin | -1084.17% |
| Profit Margin | -1972.88% |
| EBITDA Margin | -349.16% |
| EBIT Margin | -4390.36% |
| FCF Margin | -3188.05% |
Dividends & Yields
PRTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PRTC is $45, which is 154.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $45 |
| Price Target Difference | 154.8% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 0.94 |
| Piotroski F-Score | 2 |